Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

被引：0
作者：
Larry K. Golightly
Caitlin C. Drayna
Michael T. McDermott
机构：
[1] University of Colorado Hospital,Division of Endocrinology, Metabolism, and Diabetes
[2] University of Colorado Hospital Center for Drug Information,Medication Use Evaluation/Adverse Drug Reaction Coordinator
[3] Education,undefined
[4] and Evaluation,undefined
[5] University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences,undefined
[6] University of Colorado School of Medicine,undefined
[7] University of Colorado Hospital,undefined
[8] Anschutz Medical Campus Box A-003,undefined
[9] Health Sciences Library/Center for Drug Information,undefined
[10] Education,undefined
[11] and Evaluation,undefined
来源：
Clinical Pharmacokinetics | 2012年 / 51卷 / 8期
关键词：
Sitagliptin; Vildagliptin; Severe Renal Impairment; Saxagliptin; Linagliptin;
D O I：
10.1007/BF03261927
中图分类号：
学科分类号：
摘要：
Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying potential selection preferences according to individual patient variables and co-morbidities.
引用
收藏
页码：501 / 514
页数：13
相关论文
共 371 条
[1]  
Perley M.J.(1967)Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects J Clin Invest 46 1954-62
[2]  
Kipnis D.M.(1965)Intestinal factors in the control of insulin secretion J Clin Endocrinol Metab 25 1317-24
[3]  
McIntyre N.(1964)Plasma insulin response to oral and intravenous glucose administration J Clin Endocrinol Metab 24 1076-82
[4]  
Holdsworth C.D.(1964)An intestinal hormone affecting glucose disposal in man Lancet 2 672-3
[5]  
Turner D.S.(1986)Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 63 492-8
[6]  
Elrick H.(1986)Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 46-52
[7]  
Stimmler L.(2004)Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am J Physiol Endocrinol Metab 287 E199-206
[8]  
Hlad C.J.(2007)The physiology of glucagon-like peptide 1 Physiol Rev 87 1409-39
[9]  
Dupré J.(2011)Impaired regulation of the incretin effect in patients with type 2 diabetes J Clin Endocrinol Metab 96 737-45
[10]  
Nauck M.A.(2011)Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes Diabetes Care 34 S251-7
12345678910